Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.940
+0.040 (1.03%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Protara Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-76.79-64.55-49.15-43.61-37.55-47.49
Net Income
-70.02-57.44-44.6-40.42-65.95-47.25
Earnings Per Share
-1.35-1.34-2.17-3.57-5.86-4.21
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
161.85197.89170.2965.58102.26130.7
Total Debt
2.753.364.485.476.387.24
Net Cash (Debt)
159.1194.53165.8160.1195.87123.46
Net Cash Growth
12.31%17.32%175.83%-37.30%-22.34%-26.30%
Net Cash Per Share
3.084.548.055.318.5110.99

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-66.13-56.37-35.81-37.56-26.46-34.5
Capital Expenditures
-0.36-0.09-0.06-0.05-0.12-0.6
Free Cash Flow
-66.49-56.46-35.87-37.6-26.58-35.1
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.